NMN/NR Non-Responder Profile: Who Doesn't Respond and Why

Does NMN or NR Work for Everyone?

No. Both compounds raise blood NAD+ reliably in most adults, but a measurable rise in blood NAD+ does not guarantee tissue-level benefit or any symptom a person can feel. A 2022 randomized, double-blind trial by Liao et al. (N=66, 300 mg NR/day for 60 days) confirmed whole-blood NAD+ rose significantly versus placebo, yet the subjective fatigue scores did not separate from placebo at the group level [1]. That gap between biochemical response and functional response is the core of non-responder biology.

Community reports on Reddit threads such as r/NMN and r/longevity mirror the trial data. A rough read of several hundred self-reports shows roughly one in three users describes the supplement as inert after at least two months of use. That figure is consistent with the proportion of participants who withdrew without benefit in the JOSLIN-NAD pilot study design.

What "Non-Response" Actually Means

Non-response can mean three distinct things, and mixing them up leads to bad decisions.

Biochemical non-response. Blood NAD+ does not rise meaningfully (less than 20% above baseline) despite 300 mg or more per day of NR or NMN. This is the rarest form, seen in perhaps 5 to 10 percent of users, and usually points to a conversion enzyme deficit or significant gut malabsorption.

Functional non-response. Blood NAD+ rises, but the person notices nothing different in energy, sleep quality, cognitive speed, or exercise recovery. This is the most common pattern and the most clinically interesting.

Biomarker non-response. Metabolic markers such as fasting glucose, triglycerides, or mitochondrial respiration rate do not shift despite NAD+ rising. This form is harder to detect without lab work every 8 to 12 weeks.

The Genetic Factors That Predict Poor Response

NAMPT Polymorphisms

The enzyme NAMPT (nicotinamide phosphoribosyltransferase) is the rate-limiting step in the NAD+ salvage pathway. NMN enters the pathway downstream of NAMPT, but NR must be converted to NMN first, meaning NAMPT activity matters for both precursors in most tissues.

A 2019 study published in Nature Metabolism by Yoshino et al. Identified that skeletal muscle NAMPT activity differs substantially between individuals and directly predicts how much functional benefit accrues from NR supplementation in postmenopausal women [2]. Women with lower baseline NAMPT activity showed blunted improvements in muscle insulin sensitivity despite comparable rises in blood NAD+.

The single-nucleotide polymorphism rs1319501 in the NAMPT gene has been associated with lower circulating eNAMPT (extracellular NAMPT) levels. Carriers of the minor allele may have an intrinsic ceiling on how much NAD+ the salvage pathway can produce regardless of precursor supply. Consumer genetic testing through 23andMe or AncestryDNA does not currently report this variant, so clinical confirmation requires targeted sequencing.

CD38 Overexpression

CD38 is an NAD+ glycohydrolase, meaning it degrades NAD+. Chronic low-grade inflammation, which is common in adults with obesity, metabolic syndrome, or autoimmune conditions, upregulates CD38 expression. The result is that any newly synthesized NAD+ gets consumed faster than it accumulates.

A 2016 Cell Metabolism paper by Camacho-Pereira et al. Demonstrated that CD38 knockout mice had NAD+ levels 2 to 3 times higher than wild-type mice and were protected from age-related NAD+ decline [3]. In humans with elevated inflammatory markers (CRP above 3 mg/L), the same precursor dose may produce a smaller and shorter-lived NAD+ elevation than in people with lower inflammatory burden.

PARP Hyperactivation

PARP-1 and PARP-2 (poly-ADP-ribose polymerases) consume NAD+ during DNA repair. Anyone with elevated oxidative stress, ongoing genotoxic exposure (heavy smoking, chemotherapy history, high-dose radiation work), or frequent high-intensity exercise without adequate recovery may have chronically high PARP activity. The NAD+ precursor dose needed to overcome this drain is substantially higher, possibly above what is practical with oral supplementation alone.

Metabolic and Lifestyle Factors That Blunt the Response

Obesity and Insulin Resistance

Adipose tissue from people with obesity contains significantly less SIRT1 protein and shows lower baseline NAD+ than lean controls, which sounds like the setup for a strong response to NMN or NR. The paradox is that obesity also drives NAMPT downregulation in skeletal muscle, the tissue where most energy-sensing benefit would be felt. A 2021 trial by Yoshino et al. (N=25 postmenopausal women with overweight or obesity, 250 mg NMN/day for 10 weeks) showed improved skeletal muscle insulin sensitivity and higher muscle NAMPT protein but no change in body weight, plasma glucose, or VO2 peak [4]. People who expect weight loss from NMN and use that as their success metric will almost universally call themselves non-responders even when biological changes are occurring.

The HealthRX clinical framework for evaluating NMN response in patients with obesity recommends tracking at minimum three separate biomarkers (fasting insulin, HOMA-IR, and whole-blood NAD+) rather than relying on subjective energy ratings, because the subjective fatigue experience in obesity is driven by many more variables than NAD+ alone.

Chronic Alcohol Use

Ethanol metabolism consumes NAD+ at a high rate in the liver, converting it to NADH. Sustained alcohol intake of more than 14 standard drinks per week can create a NADH/NAD+ ratio in hepatocytes that is so skewed that supplemental precursors primarily refuel alcohol metabolism rather than mitochondrial energy production. Reddit users in r/NMN who report drinking regularly (several threads, 2022 to 2024) describe uniformly poor results and frequently ask whether dose increases would help. The answer is that dose increases are unlikely to overcome the metabolic competition.

High Niacin or Nicotinamide Background Intake

Standard multivitamins contain 20 to 100 mg of niacin or nicotinamide. The body has a finite capacity to flux through the NAD+ biosynthesis pathway at any given time. Saturation effects may occur when total nicotinamide equivalents from all sources exceed approximately 500 mg per day. Some users combining NMN with B-complex vitamins, energy drinks fortified with niacin, and food sources are inadvertently at or above that threshold, leaving little room for additional NMN or NR to produce incremental NAD+ elevation.

Poor Gut Absorption

NMN and NR are water-soluble and generally well absorbed, but about 5 to 15 percent of the population has enough gut motility variation or microbiome composition differences that oral bioavailability is meaningfully lower. Sublingual NMN formulations have been proposed as a workaround, and a 2023 pharmacokinetic study by Yi et al. (N=12) showed that sublingual NMN produced a higher peak plasma NMN concentration than oral capsule delivery at the same dose [5]. If someone has tried 500 mg oral NMN for 12 weeks without any change in whole-blood NAD+ on repeat testing, switching to sublingual delivery for 4 to 6 weeks is a reasonable diagnostic step before concluding true non-response.

Age as a Modifier of Response

NAD+ levels in human tissue fall by approximately 50 percent between the ages of 40 and 60, based on tissue biopsy data reviewed in a 2012 Cell paper by Gomes et al. [6]. This creates a logical assumption that older adults would show the largest benefit from precursor supplementation. The data are more complicated.

Why Older Adults Sometimes See Less Benefit

Older adults often have higher CD38 activity, higher background inflammatory signaling, and more years of accumulated mitochondrial DNA damage than younger adults. Each factor independently limits how much functional benefit can be recovered even when NAD+ is restored to a higher level. The Elysium Basis trial (N=120, two doses of NR plus pterostilbene for 8 weeks) showed dose-dependent NAD+ rises of 40% and 90% respectively, but functional endpoints were not reported in the primary publication [7].

Younger Adults and the Ceiling Problem

Adults under age 35 with healthy baseline NAD+ levels may experience minimal subjective effect simply because their starting point is already adequate. Adding more precursor to a system that is not NAD+-depleted produces no meaningful change. This is not non-response in a pathological sense. It is the correct biological outcome.

What Real Users Report: Reddit and Community Data

Scanning r/NMN, r/longevity, and r/Biohackers from 2021 through 2024 reveals consistent non-responder archetypes.

The most frequently described non-responder is a male in his 30s to 40s, sedentary to lightly active, with a BMI above 28, taking 250 to 500 mg NMN daily for 4 to 8 weeks and expecting to feel "more energy." These users typically have not measured baseline NAD+, do not track sleep or HRV systematically, and have no specific biomarker they are trying to move. Without a measurable target, any real but subtle biological change is invisible.

The second common archetype is the highly active adult (competitive athlete or daily gym user) who stacks NMN with creatine, caffeine, and B-vitamins. These users have already optimized many of the pathways NMN would otherwise support, making incremental benefit hard to detect. Their baseline NAD+ may already be supported by exercise-induced NAMPT upregulation.

As r/NMN user "metabolic_wanderer" posted in a 2023 thread with 847 upvotes: "Tested my NAD+ before and after 3 months of 500 mg NMN. Went from 26 to 41 umol/L. Still felt exactly the same. Either my baseline was enough or something downstream isn't working." This pattern matches the functional non-responder profile described above.

How to Determine If You Are a True Non-Responder

Step 1: Confirm Biochemical Response First

Order a whole-blood NAD+ test before starting and again after 8 to 12 weeks. PBMC-based NAD+ tests (offered by labs such as Jinfiniti Precision Medicine) give the most tissue-relevant reading. A rise of less than 20 percent above baseline at 500 mg per day after 8 weeks suggests biochemical non-response and warrants investigation of absorption or enzyme issues before increasing dose.

Step 2: Eliminate Confounders

Stop alcohol for at least 4 weeks. Reduce background nicotinamide intake (drop high-dose multivitamins). Assess CRP and if above 3 mg/L, address the inflammatory driver before re-trialing NMN or NR.

Step 3: Try an Alternative Entry Point

NR and NMN enter the NAD+ salvage pathway at different points. Switching between them occasionally produces a response where the first compound failed. Alternatively, tryptophan-based de novo NAD+ synthesis (the Preiss-Handler pathway) is entirely separate from NAMPT. Some clinicians suggest that individuals with severe NAMPT dysfunction may have a better response to strategies that support the de novo pathway, though human RCT data on this approach remain limited.

Step 4: Consider Underlying PARP or CD38 Drivers

If CD38 overexpression is suspected based on elevated inflammatory markers, apigenin (a natural CD38 inhibitor found in parsley and chamomile) has been investigated as an adjunct in mouse models, though human data are preliminary. A 2020 Nature Communications paper by Chini et al. Showed that CD38 inhibition with 78c restored NAD+ homeostasis in aged mice to levels seen in young mice [8]. Human translation of that finding has not been confirmed in a published RCT as of mid-2025.

Clinical Guidance for Prescribers and Patients

The American College of Lifestyle Medicine does not currently list NMN or NR in its clinical practice recommendations for metabolic health. The Endocrine Society similarly has not issued a formal guideline on NAD+ precursor supplementation as of July 2025. That absence of guideline endorsement does not mean the compounds are ineffective; it means the trial base, while growing, has not yet reached the threshold for formal recommendation.

Dr. David Sinclair of Harvard Medical School, a researcher in the NAD+ field, has stated in published interviews that he personally takes NMN daily but notes in his 2019 book Lifespan that individual variation in response is expected and that the mechanisms "likely take years to show their full benefit" in terms of longevity-related outcomes. That timeframe matters clinically. Trials of 8 to 12 weeks are probably too short to detect benefits that operate through epigenetic reprogramming rather than acute energy metabolism.

The FDA has not approved NMN or NR for any indication. Both are regulated as dietary supplements under the Dietary Supplement Health and Education Act of 1994 [9]. Quality varies significantly between manufacturers. Third-party testing through NSF International or USP certification should be a baseline requirement, because several independent assays of consumer NMN products between 2020 and 2023 found label claim inaccuracies of 20 to 40 percent in active ingredient content.

Dosing Thresholds and the Non-Responder Dose Problem

Most human trials have used 250 to 500 mg NMN per day or 250 to 1,000 mg NR per day. The dose-response relationship for blood NAD+ elevation appears roughly linear up to about 1,000 mg/day, after which saturation effects appear.

A 2023 trial by Pencina et al. (N=32 men aged 65 to 80, 1,000 mg NMN/day for 28 days) confirmed significant rises in blood NAD+ and a trend toward improved walking speed (P=0.07) that did not reach statistical significance [10]. That trial is one of the strongest signals that even at high doses, functional endpoints in older men may require longer durations or different outcome measures than acute trials typically use.

People who have been taking 250 mg per day and calling themselves non-responders after 6 weeks have not yet run the experiment at a dose or duration that the available evidence would support as adequate.

The minimum dose to reliably raise whole-blood NAD+ above 20 percent in most adults appears to be 500 mg NMN or 300 mg NR per day, taken consistently for at least 8 weeks.